Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Accumulated Expenses (2018 - 2025)

Historic Other Accumulated Expenses for Tg Therapeutics (TGTX) over the last 8 years, with Q3 2025 value amounting to $2.0 million.

  • Tg Therapeutics' Other Accumulated Expenses fell 3956.94% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 3956.94%. This contributed to the annual value of $4.6 million for FY2024, which is 21284.65% up from last year.
  • Tg Therapeutics' Other Accumulated Expenses amounted to $2.0 million in Q3 2025, which was down 3956.94% from $2.3 million recorded in Q2 2025.
  • Tg Therapeutics' Other Accumulated Expenses' 5-year high stood at $14.5 million during Q1 2021, with a 5-year trough of $807000.0 in Q3 2022.
  • For the 5-year period, Tg Therapeutics' Other Accumulated Expenses averaged around $4.1 million, with its median value being $2.0 million (2025).
  • In the last 5 years, Tg Therapeutics' Other Accumulated Expenses plummeted by 9360.94% in 2022 and then skyrocketed by 23284.19% in 2024.
  • Tg Therapeutics' Other Accumulated Expenses (Quarter) stood at $1.5 million in 2021, then dropped by 22.69% to $1.2 million in 2022, then rose by 26.52% to $1.5 million in 2023, then skyrocketed by 212.85% to $4.6 million in 2024, then plummeted by 56.93% to $2.0 million in 2025.
  • Its Other Accumulated Expenses was $2.0 million in Q3 2025, compared to $2.3 million in Q2 2025 and $2.9 million in Q1 2025.